Grimes & Company Inc. Increases Stock Holdings in The Beauty Health Company $SKIN

Key Points

• Grimes & Company Inc. increased its holdings in The Beauty Health Company by 85.2%, now owning approximately 406,987 shares worth $777,000.
• Analysts have mixed ratings on Beauty Health; while Stifel Nicolaus upgraded their price target from $3.00 to $4.00, Weiss Ratings reaffirmed a "sell" rating.
• Beauty Health's recent quarterly earnings beat expectations with $0.03 EPS reported against a consensus estimate of ($0.06), alongside revenues of $78.20 million.

Grimes & Company Inc. increased its holdings in The Beauty Health Company (NASDAQ:SKIN - Free Report) by 85.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 406,987 shares of the company's stock after buying an additional 187,226 shares during the period. Grimes & Company Inc. owned about 0.32% of Beauty Health worth $777,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Simplicity Wealth LLC purchased a new stake in shares of Beauty Health in the second quarter valued at about $49,000. Newman Dignan & Sheerar Inc. lifted its stake in Beauty Health by 28.1% in the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 91,144 shares of the company's stock valued at $174,000 after buying an additional 20,000 shares in the last quarter. Kapitalo Investimentos Ltda acquired a new stake in Beauty Health during the 2nd quarter valued at $60,000. Goldman Sachs Group Inc. increased its position in Beauty Health by 5.0% during the first quarter. Goldman Sachs Group Inc. now owns 665,706 shares of the company's stock worth $892,000 after buying an additional 31,880 shares in the last quarter. Finally, SCS Capital Management LLC acquired a new position in shares of Beauty Health in the first quarter worth $67,000. 93.26% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on SKIN shares. Stifel Nicolaus increased their price objective on Beauty Health from $3.00 to $4.00 and gave the company a "hold" rating in a research note on Friday, August 1st. Wall Street Zen raised shares of Beauty Health from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Roth Capital began coverage on shares of Beauty Health in a research report on Friday, September 19th. They issued a "buy" rating and a $3.50 price objective for the company. Cowen reissued a "hold" rating on shares of Beauty Health in a research note on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Beauty Health in a research note on Saturday, September 27th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $2.81.

Beauty Health Stock Performance

Shares of SKIN stock opened at $1.67 on Tuesday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 4.15 and a current ratio of 5.15. The firm has a market capitalization of $211.79 million, a price-to-earnings ratio of -5.96 and a beta of 1.21. The Beauty Health Company has a one year low of $0.78 and a one year high of $2.69. The company has a 50 day moving average price of $2.05 and a 200 day moving average price of $1.70.

Beauty Health (NASDAQ:SKIN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. The company had revenue of $78.20 million during the quarter, compared to analysts' expectations of $74.67 million. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that The Beauty Health Company will post -0.25 EPS for the current year.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.